genOway S.A.
ALGEN.PA
Euronext Paris2.35
EUR
-0.08
- -
genOway S.A.
ALGEN.PA
(Euronext Paris)
Recent
price
2.35
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- genOway S.A. specializes in the development and commercialization of custom genetically modified mouse, rat, and cellular models primarily for the biopharmaceutical, academic, and research sectors. Its core product offerings include bespoke knockout (KO) and knockin (KI) mouse models; constitutive and conditional KO, point mutation KI, and quick KI rat models; as well as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company provides advanced technological solutions for transgenesis and model design, including site-specific transgenesis, random insertion transgenic models, gene overexpression, humanization, gene deletion, and RNA interference-mediated gene knock-down. genOway also delivers interactive scientific consulting throughout the research project cycle to tailor models to specific research objectives and enhance study reliability. Founded in 1999 and headquartered in Lyon, France, genOway operates globally, serving over 170 life sciences companies, including 17 of the top 20 global pharmaceutical firms, and more than 380 academic institutions. It holds exclusive licenses on key patented technologies used in its model creation, including the foundational CRISPR/Cas9 patents from Merck, ensuring clients freedom to operate. The company has recently accelerated growth through its joint venture genOway Shanghai, which targets the Chinese and broader Asian markets with immuno-oncology models, aiming for profitability and doubling revenue by 2026. This expansion supports genOway’s strategic plan called Route 50+, aiming to exceed €50 million in revenue by 2028 through product innovation and commercial team reinforcement. Additionally, genOway continues to develop new translational cancer and immunotherapy models and has consolidated strategic collaborations in immune checkpoint model development. genOway’s business segments focus on genetically engineered preclinical models across oncology, immunology, neurosciences, metabolism, and other biomedical research fields. The company maintains a diverse portfolio of off-the-shelf knockout and reporter models widely used in fundamental and applied sciences. Its global operation footprint includes strong presence and client bases in Europe, the United States, and Asia, supported by a local production unit in Shanghai. genOway’s latest major operational changes include the establishment of this Shanghai subsidiary, expansion in immuno-oncology model offerings, and strategic partnerships that fortify its market position in both pharmaceutical and academic research sectors.